Anti-Hypertensive Drugs - Italy

Italy

Highlights

in Italy, a country known for its rich history and cultural heritage, is also a significant player in the Anti-Hypertensive Drugs market.
According to projections, the revenue in this market is expected to reach a substantial US$342.30m in 2024.
This promising figure is indicative of the growing demand for Anti-Hypertensive Drugs market in Italy.
Looking ahead, it is anticipated that the market will continue to grow steadily, with an estimated annual growth rate (CAGR 2024-2029) of -0.77%.
This growth trajectory is likely to result in a market volume of US$329.30m by 2029, further solidifying Italy's position in the Anti-Hypertensive Drugs market.
In a global context, it is worth noting that United States is expected to generate the highest revenue in this market, with a staggering US$12.29bn projected for 2024.
This highlights the dominance of the United States in the Anti-Hypertensive Drugs market and underscores the importance of international comparison when analyzing market trends.
Italy's market for anti-hypertensive drugs is experiencing a surge in demand due to the country's aging population and high prevalence of hypertension.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Anti-Hypertensive Drugs market in Italy has seen significant growth in recent years.

Customer preferences: Italian customers are increasingly concerned about their health and are seeking ways to manage their blood pressure. This has led to a growing demand for anti-hypertensive drugs in the country. Patients are also becoming more aware of the potential side effects of these drugs and are looking for safer, more effective options.

Trends in the market: One of the key trends in the Anti-Hypertensive Drugs market in Italy is the increasing use of combination therapies. These drugs combine two or more active ingredients to provide a more effective treatment for hypertension. Another trend is the growing popularity of generic drugs, which are cheaper than their branded counterparts and offer a more affordable option for patients.

Local special circumstances: Italy has a large aging population, which is driving demand for anti-hypertensive drugs. The country also has a high prevalence of hypertension, with around one in four adults suffering from the condition. This has led to a growing need for effective treatments that can help manage blood pressure and reduce the risk of related health problems.

Underlying macroeconomic factors: The Italian pharmaceutical market is highly regulated, which has led to some challenges for drug manufacturers operating in the country. However, the government has recently implemented a number of measures to improve access to healthcare and reduce the cost of prescription drugs. This is expected to drive further growth in the Anti-Hypertensive Drugs market in Italy in the coming years. Additionally, the COVID-19 pandemic has highlighted the importance of managing underlying health conditions, including hypertension, which is likely to further boost demand for anti-hypertensive drugs.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.